Research programme: degenerative and metabolic disorder therapeutics - Prothena Corporation

Drug Profile

Research programme: degenerative and metabolic disorder therapeutics - Prothena Corporation

Alternative Names: Islet amyloid polypeptide antibodies - Prothena; PRX 004

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Neotope Biosciences
  • Developer Neotope Biosciences; Prothena
  • Class Monoclonal antibodies
  • Mechanism of Action Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyloidosis; Metabolic disorders; Neurodegenerative disorders
  • Research Age-related macular degeneration

Most Recent Events

  • 24 Feb 2017 Prothena has patent protection for PRX 004 (Prothena's form 10-K, filed in February 2017)
  • 01 Nov 2016 Prothena plans clinical development for Amyloidosis in 2017-2018
  • 16 Mar 2016 Preclinical development in Amyloidosis is ongoing Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top